PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
39.22%
Revenue growth under 50% of CSIQ's 130.82%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
64.11%
Gross profit growth under 50% of CSIQ's 692.55%. Michael Burry would be concerned about a severe competitive disadvantage.
165.49%
EBIT growth below 50% of CSIQ's 1313.33%. Michael Burry would suspect deeper competitive or cost structure issues.
49.95%
Operating income growth under 50% of CSIQ's 219.95%. Michael Burry would be concerned about deeper cost or sales issues.
245.39%
Net income growth at 50-75% of CSIQ's 469.32%. Martin Whitman would question fundamental disadvantages in expenses or demand.
325.00%
EPS growth at 50-75% of CSIQ's 484.62%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
316.67%
Diluted EPS growth at 50-75% of CSIQ's 476.92%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
8.51%
Slight or no buybacks while CSIQ is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
17.51%
Diluted share count expanding well above CSIQ's 1.05%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
105.32%
OCF growth of 105.32% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
53.59%
FCF growth of 53.59% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
251.78%
10Y revenue/share CAGR under 50% of CSIQ's 3502.19%. Michael Burry would suspect a lasting competitive disadvantage.
251.78%
5Y revenue/share CAGR under 50% of CSIQ's 3502.19%. Michael Burry would suspect a significant competitive gap or product weakness.
283.50%
3Y revenue/share CAGR similar to CSIQ's 278.96%. Walter Schloss would assume both companies experience comparable short-term cycles.
-97.12%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-97.12%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-56.68%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
143.82%
Below 50% of CSIQ's 3606.88%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
143.82%
Below 50% of CSIQ's 3606.88%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
87.49%
Below 50% of CSIQ's 419.21%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.40%
Below 50% of CSIQ's 1008.85%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
96.93%
AR growth well above CSIQ's 63.74%. Michael Burry fears inflated revenue or higher default risk in the near future.
-23.39%
Inventory is declining while CSIQ stands at 6.64%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
16.24%
Similar asset growth to CSIQ's 15.37%. Walter Schloss finds parallel expansions or investment rates.
7.98%
1.25-1.5x CSIQ's 6.23%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
43.10%
Debt growth far above CSIQ's 16.97%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-13.03%
Our R&D shrinks while CSIQ invests at 12.77%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
0.79%
SG&A declining or stable vs. CSIQ's 50.63%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.